By Amber Dance

Biden extends pandemic rescue funds for affordable housing

The Treasury Department released new guidelines that will make it easier for state and local governments to apply COVID relief funds to affordable housing projects, reports Joey Garrison at USA Today.

Cities and states have already spent $12.9 billion from 2021’s $350 billion American Rescue Plan on housing.

Now, there will be fewer restrictions on governments’ use of additional relief dollars for loans to nonprofits and developers building affordable housing.

The move also allows governments to direct relief funds to several federal housing programs, such as low-income housing credits and housing for people who are elderly or disabled.

“This is a major win for increasing housing stock and lowering the cost of housing for thousands of Americans,” said Rep. Alma Adams (D-N.C.), who co-sponsored legislation to allow this change.

Fall booster push moved up to September

Pfizer and Moderna have now promised to deliver millions of improved, ómicron-targeting vaccines to the United States by September, a month earlier than previously expected.

With an expectation of boosters in hand so soon, the Biden administration has scrapped plans to release a summer booster with the original vaccine formula. It wouldn’t be effective to get two boosters in such close proximity, and doing so might even raise the risk of myocarditis, an inflammation of the heart, as a side effect.

“Officials agreed on the goal of strengthening everyone’s immunity in the fall with what is hoped will be a more effective booster, ahead of a possible winter surge,” write Noah Weiland and Sharon LaFraniere at The New York Times.

The pair report that all adults will be eligible for the new boosters, and children might be eligible as well.

The Biden administration has purchased 105 million doses of Pfizer’s vaccine, and 66 million Moderna doses. The U.S. has an option to purchase more — enough for all 330 Americans — but would require additional money from Congress to do so, reports Naomi Thomas at CNN.

The updated boosters would still require FDA authorization and CDC recommendation before use. 

Summit plans for future COVID vaccines, but where’s the money?

The first generation of coronavirus vaccines has saved 20 million lives worldwide, but the White House thinks it can be improved upon.

The Biden administration convened an optimistic “Summit on the Future of COVID-19 Vaccines” last Tuesday. It was “likely the largest indoor gathering of U.S. public health leaders since the pandemic began,” quips Lev Facher at STAT.

Next-gen vaccines might be delivered to the nose with an inhaled mist, triggering antibodies that stop the virus right where it attempts to enter the body. Or they might be needle-free, coming via a skin patch covered in tiny, painless micro-spikes.

They might even create immunity against future, unknown variants.

Conference attendees were upbeat about these prospects, Facher reports, but admitted none of it would happen with billions of dollars from a Congress that has been reluctant to release more money to combat the pandemic. 

The current vaccines resulted in great part from the Trump administration’s Operation Warp Speed, which spent $18 billion on COVID vaccines.

One official told Facher a funding request for as much as $12 billion is being prepared.

“We need vaccines that are durable,” said White House COVID coordinator Dr. Ashish Jha. “We need vaccines that are broader and offer longer-lasting protection. We need a vaccine that can stand up to multiple variants. Ultimately, we need vaccines that can protect us no matter what Mother Nature throws at us.” 

These new vaccines could take three to five years, or longer, to develop, writes Cheyenne Haslett at ABC News. Jha expressed hope that timeline could be cut drastically if a large government investment were made.

Few families choose vaccination for youngest children

Just one month into vaccine eligibility for children younger than 5, the last group to be granted access, interest has already begun to wane, according to an analysis by the Kaiser Family Foundation.

By July 20, about 544,000 children under age 5 had started the vaccine series — just 2.8% of the 19 million newly eligible kids. The number of children getting vaccinated has been dropping since the beginning of July.

For comparison, 18.5% of children ages 5 through 11 had received their first dose one month after they became eligible. Eight months in, only 30% have completed a vaccination course. 

The District of Columbia has the highest uptake, with 14.4% of young kids starting vaccination, while Mississippi had the lowest share at 0.4%. In Florida, the only state not to pre-order vaccines from the government, 1% of young children have received their first dose.

KFF analysts attributed the low uptake, in part, to fewer locations where young kids can be vaccinated. Washington Post columnist Alyssa Rosenberg notes that D.C. set up vaccination clinics all over the city, with weekend and late hours, making access easy.

“Public health officials should make sure logistics aren’t keeping kids from getting vaccinated,” she writes. 

Another issue is parental caution about trying the shots, especially since many parents perceive the pandemic as less of an emergency now than it was when vaccines arrived for adults and older kids.

KFF’s latest Vaccine Monitor survey found that 53% of parents of kids younger than 5 viewed the vaccine as a greater threat to their child’s health than the virus itself. 

Many Black parents reported it would be difficult to take time off work to get the vaccine and deal with potential side effects, notes James Lopilato at MedPage Today. Hispanic parents were concerned about finding a trustworthy vaccination site and the potential cost of the vaccine. (The vaccines are free.)

Health experts were alarmed by the results, reports Jan Hoffman at The New York Times. Patricia A. Stinchfield, president of the National Foundation for Infectious Diseases, noted that “some kids get very, very ill from [the virus] and some die.”

Long-lasting symptoms can also occur in children. A recent study found that 5.8% of kids had problems like fatigue or cough 90 days following COVID infection, reports Elizabeth Short at MedPage Today.

Find your latest news here at the Hemet & San Jacinto Chronicle

The post Coronavirus Files: Boosters coming in September, while inoculation of youngest kids stagnates appeared first on The Hemet & San Jacinto Chronicle.

Uninsured suffered unnecessary deaths during pandemic

Universal health care could have saved more than 338,000 lives in the U.S. during the pandemic, according to a new study in the Proceedings of the National Academy of Sciences.

That’s more than one-quarter of the nation’s estimated COVID deaths, according to the study led by researchers at the Yale School of Public Health.

They calculated that universal health care could also have saved the nation $105.6 billion in hospitalization costs.

More than 28 million adults were uninsured before COVID-19 hit, and a more than 9 million additional people lost their health insurance due to the surge in unemployment caused by the pandemic.

The study pointed to several factors by which health insurance could have saved lives. Uninsured people tend to lack a primary care physician, putting them at higher risk for preventable diseases such as diabetes that can complicate COVID-19.

Those without insurance are also likely to wait longer to seek testing or medical attention when they get sick, which could make them not only less likely to survive, but more likely to transmit the virus to others.

Individuals without a primary physician also have lower vaccination rates, further increasing their risk of dying from COVID.

The study’s count of avoidable deaths may be an underestimate, reports Rachel Nuwer at Scientific American. UC Berkeley public health expert Ann Keller, who wasn’t involved in the study, told her that universal health care would likely lead to lower rates of chronic disease as well as better management of chronic conditions, which would help protect people from the worst of COVID’s effects.

FDA, CDC OK vaccines for children as young as 6 months

After a slew of regulatory meetings, young children will finally be able to receive their first COVID-19 vaccines this week.

The FDA granted emergency authorization to Moderna’s vaccine for children from 6 months to 5 years years, and to Pfizer’s for 6 months to 4 years. The CDC then officially recommended that all children age 6 months or older receive vaccination, either brand.

Each vaccine resulted in antibody levels comparable to those of older individuals after vaccination, the primary goal for a pediatric vaccine trial.

The FDA’s Dr. Peter Marks noted the preschool age group could benefit from protection against the coronavirus. At least 442 children under age 4 have died of COVID in the U.S. And half of them had no preexisting conditions to suggest they were at higher risk.

Older children were already eligible for a Pfizer vaccine. The FDA authorized Moderna’s vaccine for children 6 and up last week.

Moderna’s pediatric authorization had been delayed by concerns about the vaccine’s higher rates of heart inflammation, or myocarditis, compared to Pfizer’s. But more recent data suggest the risk is similar between the two vaccines. The risk of myocarditis is highest among teen boys.

“That [myocarditis data] clearly needs to be watched going forward,” said Dr. Mark Sawyer of UC San Diego, a member of the FDA’s outside advisory committee.

The CDC’s advisory committee plans to take up Moderna’s application for ages 6 through 17 on June 23.

While some parents have been desperately awaiting the approval of vaccines for young children, the majority likely won’t likely be rushing to the clinic. According to the most recent Kaiser Family Foundation poll, 18% of parents plan to get their under-5 kids vaccinated immediately, with another 38% expect to wait and see for a bit.

FDA advisors emphasized the importance of choice for parents, and now families who want the vaccine must make them — first whether to vaccinate their young children, and if so, which vaccine to give them. That’s a tricky calculation.

“[FDA] Committee members spent much of the question-and-answer period Wednesday trying to understand whether one COVID-19 vaccine is more effective in small children than the other, but they were frustrated by the lack of data,” writes Karen Weintraub at USA Today.

Pfizer tested its vaccine, at one-tenth the dosage of the adult shot, in 4,526 kids between 6 months and 4 years old. It settled on a three-dose course, which will take three months to complete.

Efficacy against infection was nearly zero after just two doses. After three doses, Pfizer reported an efficacy of 80.3%, but that was based on a small number of cases — just three cases in kids who were vaccinated compared to seven among those who got placebo.

The vaccine’s true efficacy could be anywhere between 14% and 81%. “We should just assume we don’t have efficacy data,” said Dr. Sarah Long of Drexel University, a member of the CDC’s vaccine advisory committee.

Pfizer’s requirement for three doses could be a “logistical nightmare” for families, notes Helen Branswell at STAT. “Adding three more doctor visits to get three doses of COVID vaccines — that’s asking a lot of families.”

Moderna’s vaccine, which relies on one-quarter of the adult dose, was tested in 6,607 children between 6 months and 5 years old. The two-dose series resulted in antibody levels comparable to vaccinated adults within 6 weeks. Efficacy against infection ranged from 31% to 51%.

That efficacy, which is lower than what Moderna reported for trials in older kids and adults, is likely related to the prevalence of the omicron variant during the trial. The company is already testing its two-part booster with original coronavirus and omicron-specific mRNA in young kids, with results expected this summer. That could further enhance protection.

Side effects such as fever were higher in the Moderna study, likely due to the higher dose of vaccine. There were no cases of myocarditis in either study, though that doesn’t mean this couldn’t appear once a larger group of children is vaccinated.

So, what’s a parent to do? Epidemiologist Katelyn Jetelina wrote on her blog that she’ll get Moderna for her daughters, but noted, “You cannot make a wrong decision. Each vaccine is better than nothing, and both help with severe disease and death.”

The White House plans to make the vaccines for young kids available at a variety of locations, including pediatrician’s offices. Every state but one has already preordered the doses for kids.

The Department of Health in Florida, the lone holdout, cited a “convoluted” distribution process and its policy that doesn’t advise vaccination for all children, writes Arek Sarkissian at Politico.

Florida children will still be able to access vaccines from physicians or pharmacies, such as CVS, that order them directly from the federal government.

There are no plans to vaccinate children younger than 6 months, but they can have some protection if their mothers are vaccinated, with immunity transferred during pregnancy and via breastmilk.

Paxlovid falters for medium-risk individuals

The antiviral Paxlovid can protect high-risk individuals from the worst effects of a COVID infection, but it doesn’t do much to speed recovery from symptoms in people of “standard” risk, drugmaker Pfizer reported last week.

Those at high risk include older individuals and people with health conditions ranging from diabetes to weakened immune systems to heart conditions. In other words, the medicine is still indicated for a wide swath of the American population, for whom it can prevent hospitalization and death.

But for others, the benefits may be negligible. The drug also didn’t pass statistical tests for a significant reduction in hospitalization or death in people who’d been vaccinated against COVID.

“Paxlovid is not going to have a big role in vaccinated people, except in people who are maybe at highest risk,” Dr. Walid Gellad of the University of Pittsburgh told STAT.

Pfizer said that going forward, it will focus on studying Paxlovid in high-risk populations, such as people who are immunocompromised.

Another recent study from Mayo Clinic researchers found that a rebound of symptoms after Paxlovid, reported in a series of anecdotes that set off alarm bells, is a rare event. Only four out of 483 patients experienced a resurgence of symptoms after completing Paxlovid treatment, reports Elizabeth Short at MedPage Today.

Most of the subjects in that Mayo Clinic trial were vaccinated and boosted against COVID, and few were immunocompromised.

While Paxlovid is the leading COVID-19 treatment available to take at home for now — Merck’s molnupiravir is less effective — it has its problems and likely to be supplanted by something better, writes Hannah Doctor-Loeb at Slate.

The drug can cause side effects including a nasty aftertaste and diarrhea.

For many people, it’s not an option at all because Paxlovid is contraindicated for people who take certain other medications, including some anticonvulsants and cardiovascular drugs.

Another reason to develop more COVID medicines is that regular use of Paxlovid could push the coronavirus to evolve resistance to the drug. Some researchers are experimenting with multi-drug cocktails that would make it harder for the virus to achieve resistance.

Those researchers may hit a snag when they go to test their drugs in people, though. The number of vaccines and other treatments already available means there are fewer and fewer patients willing to participate in those clinical trials, reports Saima May Sidik at Nature.

It would take a large number of volunteers to prove that a new medicine is better than what’s available, said Dr. Elizabeth Hohmann of Massachusetts General Hospital: “You’d have to have a real game changer to take on Paxlovid.”

Find your latest news here at the Hemet & San Jacinto Chronicle

The post Coronavirus Files: Feds authorize vaccines for youngest kids appeared first on The Hemet & San Jacinto Chronicle.